enzastaurin has been researched along with Diffuse Large B-Cell Lymphoma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Brody, J; Cao, J; Han, I; Heineman, T; Jing, H; Jivani, M; Lansigan, F; Li, L; Liu, Y; Lue, JK; Luo, W; Maly, J; Nowakowski, GS; Rizvi, S; Smith, SD; Song, Y; Sun, J; Sun, X; Zhang, L; Zhang, Q; Zhu, J | 1 |
| Deng, L; Ding, N; He, Y; Li, J; Liu, W; Ping, L; Song, Y; Wang, X; Xie, Y; Ying, Z; Zhang, C; Zhu, J | 1 |
| Arrowsmith, ER; Fayad, LE; Hainsworth, JD; Hamid, O; Hsi, ED; Lin, BK; McCleod, M; Shi, P | 1 |
| Cai, R; Cui, Y; Fang, X; Fu, X; Hong, H; Huang, H; Li, S; Li, X; Lin, T; Lin, X; Yang, N; Zhang, W | 1 |
| Crump, M; Di Rocco, A; Fayad, L; Habermann, T; Hagberg, H; Hahka-Kemppinen, M; Hsi, ED; Kahl, B; Lee, JJ; Leppä, S; Lin, B; Mackensen, A; Nguyen, T; Offner, F; Ogura, M; Pinter-Brown, L; Rifkin, R; Savage, KJ; Schmitz, N; Schnell, F; Shi, P; Smith, S; Thornton, D; Tobinai, K; Yeh, SP | 1 |
| Barrientos, J; Elstrom, R; Leonard, JP; Martin, P | 1 |
| Ogura, M | 1 |
| Aster, JC; Cruz, JC; Darstein, C; de Vos, S; Enas, N; Flynn, PJ; Goldberg, SL; Kahl, BS; Kutok, JL; LaCasce, A; Laughlin, M; Musib, L; Neuberg, D; Robertson, MJ; Rowland, K; Savage, KJ; Shipp, MA; Slapak, CA; Thornton, D; Vose, JM | 1 |
2 review(s) available for enzastaurin and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Targeted treatment and new agents in diffuse large B-cell lymphoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Delivery Systems; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Inhibitor of Apoptosis Proteins; Lymphoma, Large B-Cell, Diffuse; Microtubule-Associated Proteins; Neoplasm Proteins; Protease Inhibitors; Protein Kinases; Pyrazines; Survivin; TOR Serine-Threonine Kinases; Treatment Outcome; Vorinostat | 2008 |
[Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Gene Targeting; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Nitrogen Mustard Compounds; Prednisone; Prognosis; Purine Nucleosides; Pyrimidinones; Risk; Rituximab; Salvage Therapy; Sirolimus; Transplantation, Autologous; Vincristine | 2008 |
5 trial(s) available for enzastaurin and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Doxorubicin; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Indoles; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Research Design; Rituximab; Vincristine | 2020 |
A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Indoles; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Treatment Outcome; Vincristine | 2016 |
A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma.
Topics: Adult; Aged; Asian People; Female; Humans; Indoles; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms | 2016 |
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Double-Blind Method; Doxorubicin; Female; Humans; Indoles; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Protein Kinase C beta; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Rituximab; Vincristine | 2016 |
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Immunohistochemistry; Indoles; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Recurrence | 2007 |
1 other study(ies) available for enzastaurin and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Gene Expression Regulation; Humans; Indoles; Lymphoma, Large B-Cell, Diffuse; Mice; Piperidines; Pyrazoles; Pyrimidines; Transcriptome; Xenograft Model Antitumor Assays | 2019 |